Nasal-Spray Millionaire: Indivior's Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment
Portfolio Pulse from Vandana Singh
The FDA has approved Indivior's Opvee nasal spray for emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older. Indivior acquired the product from Opiant Pharmaceuticals and expects annual net revenue of $150 million to $250 million from Opvee.
May 23, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Emergent BioSolutions' Narcan, a similar product to Opvee, was approved by the FDA in March for nonprescription use.
Emergent BioSolutions' Narcan, a product similar to Opvee, was approved by the FDA in March for nonprescription use. The approval of Opvee may introduce competition for Narcan, which could negatively impact Emergent BioSolutions' stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Indivior's Opvee nasal spray receives FDA approval for opioid overdose treatment, with expected annual net revenue of $150 million to $250 million.
The FDA approval of Opvee is a significant milestone for Indivior, as it expands their product portfolio and opens up a new revenue stream. The expected annual net revenue of $150 million to $250 million will likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Indivior acquired Opvee from Opiant Pharmaceuticals, which may benefit from the FDA approval and expected revenue.
Opiant Pharmaceuticals, the original developer of Opvee, may see a positive impact on its stock price due to the FDA approval and expected revenue for Indivior. However, the direct impact on Opiant's stock price may be limited as they have already sold the product to Indivior.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50